ReviewCurrent cardiology reports2020
Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?
Review in Current cardiology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 59 citations in OpenAlex.
- Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.Arteriosclerosis, thrombosis, and vascular biology · 2025Trial
- Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.Circulation · 2022Trial
- Higher APOB is associated with poor renal outcome in lupus nephritis.Clinical rheumatology · 2026Article
- Association of the Discordance Between Apolipoprotein B and Low-Density Lipoprotein Cholesterol With Cognition.Journal of the American Heart Association · 2026Article
- Metabolic reprogramming in the enterocytes of neonatal piglets infected with porcine epidemic diarrhea virus: integrated omics and multi-batch analysis highlight alterations in lipid metabolism and potential therapeutic targets.Microbiology spectrum · 2026Article
- Significant correlations between blood lipids, cytokines, and C-reactive protein in healthy humans.Lipids in health and disease · 2026Article
- Apolipoprotein B in cardiovascular risk assessment: beyond traditional lipid markers.Frontiers in cardiovascular medicine · 2026Review
- Cardiometabolic Biomarkers and Cardiovascular Risk Stratification in Polish Military Personnel: A Chemometric Approach.International journal of molecular sciences · 2025Article
- Association between Apolipoprotein B and diabetic nephropathy: insights from the National Health and Nutrition Examination Survey 2007-2016 and Mendelian randomization analysis.Nutrition & diabetes · 2025Observational
- Can we trust published evidence on point-of-care tests for cholesterol? A rapid review.BMJ open · 2025Review
- Clinical significance of small dense low-density lipoprotein cholesterol measurement in type 2 diabetes.Journal of diabetes investigation · 2025Review
- Review
- Mass-spectrometric analysis of APOB polymorphism rs1042031 (G/T) and its influence on serum proteome of coronary artery disease patients: genetic-derived proteomics consequences.Molecular and cellular biochemistry · 2024Article
- Trends in epidemiology of dyslipidemias in India.Indian heart journal · 2024Review
- Closing the gaps in patient management of dyslipidemia: stepping into cardiovascular precision diagnostics with apolipoprotein profiling.Clinical proteomics · 2024Review
- ApoB100 and Atherosclerosis: What's New in the 21st Century?Metabolites · 2024Review
- Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape-focus on hypertriglyceridaemia.Frontiers in cardiovascular medicine · 2024Review
- Stratification in Heterozygous Familial Hypercholesterolemia: Imaging, Biomarkers, and Genetic Testing.Current atherosclerosis reports · 2023Review
- Changes in the cholesterol profile of patients with rheumatoid arthritis treated with biologics or Janus kinase inhibitors.Journal of rheumatic diseases · 2023Article
- Use of Apolipoprotein B in the Era of Precision Medicine: Time for a Paradigm Change?Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewGuidelines propose using non-HDL cholesterol or apolipoprotein (apo) B as a secondary treatment target to reduce residual cardiovascular risk of LDL-targeted therapies. This review summarizes the strengths, weaknesses, opportunities, and threats (SWOT) of using apoB compared with non-HDL cholesterol. RECENT
findingsNon-HDL cholesterol, calculated as total-HDL cholesterol, includes the assessment of remnant lipoprotein cholesterol, an additional risk factor independent of LDL cholesterol. ApoB is a direct measure of circulating numbers of atherogenic lipoproteins, and its measurement can be standardized across laboratories worldwide. Discordance analysis of non-HDL cholesterol versus apoB demonstrates that apoB is the more accurate marker of cardiovascular risk. Baseline and on-treatment apoB can identify elevated numbers of small cholesterol-depleted LDL particles that are not reflected by LDL and non-HDL cholesterol. ApoB is superior to non-HDL cholesterol as a secondary target in patients with mild-to-moderate hypertriglyceridemia (175-880 mg/dL), diabetes, obesity or metabolic syndrome, or very low LDL cholesterol < 70 mg/dL. When apoB is not available, non-HDL cholesterol should be used to supplement LDLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.